by Clinical Neuropsychologist Online | Monday, September 23, 2024 | Neuropsychology (general)
Journal of Neuropsychology, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Paul M. Jenkinson, Valentina Moro | September 23, 2024 Wiley:...
by Clinical Neuropsychologist Online | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION The microglial receptor triggering receptor expressed on myeloid cells 2 (TREM2) is a major risk factor for Alzheimer’s disease (AD). Experimentally, Trem2 deficiency affects parenchymal amyloid beta (Aβ) deposition. However, the role of...
by Clinical Neuropsychologist Online | Monday, September 23, 2024 | Neurorehabilitation
Volume 27, Issue 7, October 2024, Page 243-250. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Kennea Martins Almeida Ayupe Amanda Larissa Oliveira Lima...
by Clinical Neuropsychologist Online | Monday, September 23, 2024 | Neurorehabilitation
Volume 27, Issue 7, October 2024, Page 235-242. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Michèle Widmer Alice Minghetti Jacqueline Romkes Martin...
by Clinical Neuropsychologist Online | Sunday, September 22, 2024 | Dementia
Abstract The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer’s disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks,...
